Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1446274
Archemix Corp. - Product Pipeline Review - Q4 2010
Description:
Archemix Corp. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Archemix Corp. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Archemix Corp. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Archemix Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Archemix Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Archemix Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Archemix Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Archemix Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Archemix Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Archemix Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Archemix Corp. and identify potential opportunities in those areas.
Summary
Global Market Direct’s pharmaceuticals report, “Archemix Corp. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Archemix Corp. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Archemix Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Archemix Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Archemix Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Archemix Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Archemix Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Archemix Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Archemix Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Archemix Corp. and identify potential opportunities in those areas.
Contents:
List of Tables
List of Figures
Archemix Corp. Snapshot
Archemix Corp. Overview
Key Information
Key Facts
Archemix Corp. – Research and Development Overview
Key Therapeutic Areas
Archemix Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Archemix Corp. – Pipeline Products Glance
Archemix Corp. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Archemix Corp.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Archemix Corp. – Drug Profiles
ARC1779
Product Description
Mechanism of Action
R&D Progress
ARC19499
Product Description
Mechanism of Action
R&D Progress
ARC1905
Product Description
Mechanism of Action
R&D Progress
Aptamers For Hemophilia
Product Description
Mechanism of Action
R&D Progress
Aptamers for Sicke Cell Disease
Product Description
Mechanism of Action
R&D Progress
Sickle Cell Disease Program
Product Description
Mechanism of Action
R&D Progress
Archemix Corp. – Pipeline Analysis
Archemix Corp. – Pipeline Products by Therapeutic Class
Archemix Corp. Pipeline Products By Target
Archemix Corp. – Pipeline Products by Route of Administration
Archemix Corp. – Pipeline Products by Molecule Type
Archemix Corp. – Locations And Subsidiaries
Head Office
Recent Developments
Mar 30, 2009: Archemix Initiates Phase IIa For Lead Aptamer Product Candidate ARC1779
Jan 27, 2009: Archemix Initiates Phase IIb Trial For Lead Aptamer Product Candidate ARC1779
Dec 04, 2008: Archemix Announces That ARC1779 Data To Be Presented At Upcoming American Society Of Hematology (ASH) Annual Meeting
Oct 27, 2008: Ophthotech Enrolls First Patient In A Phase I Complement (Anti-C5) Inhibitor Trial For Macular Degeneration
Jul 09, 2008: Archemix’ ARC1779 Granted Orphan Designation In EU For The Treatment Of TTP, A Life-Threatening Blood Disorder
Apr 22, 2008: Archemix’ ARC1779 Granted Orphan Designation For The Treatment of TTP, A Life-Threatening Blood Disorder
Mar 17, 2008: Archemix Announces Initiation Of Phase II Trial For Aptamer Product Candidate ARC1779 In Patients With TTP, A Rare, Life-Threatening Blood Disorder
Nov 13, 2007: Archemix Announces Initiation Of Phase 2a Trial For Aptamer Product Candidate ARC1779 In Patients With Acute Coronary Syndrome
Jun 08, 2007: Archemix Announces Completion Of Phase I Trial Of ARC1779
Jan 03, 2007: Archemix Announces Initiation Of Phase I Clinical Trial For Novel, Selective Anti-Platelet Aptamer (ARC1779)
Financial Deals Landscape
Archemix Corp., Deals Volume Summary, 2004 to YTD 2010
Archemix Corp., Deals Summary By Region, 2004 to YTD 2010
Archemix Corp., Deals Summary, 2004 to YTD 2010
Archemix Corp. Detailed Deal Summary
Venture Financing
Archemix Secures $50 Million In Series B Financing
miRagen Therapeutics Enters Into A Co-Development Agreement With Archemix
Archemix Enters Into Co-Development Agreement With Dicerna Pharmaceuticals
GlaxoSmithKline Enters Into Agreement With Archemix
Takeda Pharmaceutical Enters Into An Agreement With Archemix
Merck Serono Enters Into Agreement With Archemix
Merck Signs Agreement With Archemix
Archemix Enters Into Collaboration Agreement With Pfizer
Archemix Enters Into Research And Development Agreement With Elan
Licensing Agreements
Archemix Enters Into Licensing Agreement With Eli Lilly
Archemix Enters Into Licensing Agreement With NascaCell
Isis Pharmaceuticals Enters Into Research Collaboration And Licensing With Archemix
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Saturday, May 25, 2013
9:47:39 PM
9:47:39 PM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Archemix Corp. - Product Pipeline Review - Q4 2010
Web Address
http://www.researchandmarkets.com/reports/1446274
Office Code
OC8DIQSMLPUVQR
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (PDF) - Single User |
|
EURO€ 384.00 |
|---|---|---|
| Electronic (PDF) - Site License |
|
EURO€ 769.00 |
| Electronic (PDF) - Enterprisewide |
|
EURO€ 1,153.00 |
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Saturday, May 25, 2013
9:47:39 PM
9:47:39 PM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp